Related Experiment Video
Updated: Oct 18, 2025
06:24
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
Published on: October 13, 2023
1.2K
Arbutin Ameliorates Murine Colitis by Inhibiting JAK2 Signaling Pathway.
Liang Wang1,2, Yuntao Feng1, Jianwen Wang1
1Comparative Medicine Department of Researching and Teaching, Dalian Medical University, Dalian, China.
Frontiers in Pharmacology
|October 1, 2021
Summary
Arbutin, a natural compound, effectively treats colitis in mice by inhibiting Janus kinase 2 (JAK2) signaling. This study reveals arbutin
Area of Science:
- Pharmacology
- Immunology
- Gastroenterology
Background:
- Janus kinase 2 (JAK2) activation drives inflammatory bowel disease (IBD) pathogenesis.
- Arbutin, a natural product, shows potential for JAK2 inhibition via docking studies.
Purpose of the Study:
- To investigate arbutin's effects on a mouse colitis model.
- To elucidate the mechanism of arbutin in regulating JAK2 signaling in colitis.
Main Methods:
- Established a dextran sulfate sodium-induced colitis mouse model.
- Assessed inflammation in epithelial and immune cells after lipopolysaccharide (LPS) stimulation.
- Administered arbutin and JAK2 inhibitor AG490 to evaluate treatment efficacy.
Main Results:
- Arbutin significantly alleviated colitis symptoms, including weight loss and colon damage.
- Arbutin suppressed pro-inflammatory cytokines and apoptosis markers in the colon.
- Arbutin reversed elevated phosphorylated JAK2 levels and inhibited LPS-induced inflammation, effects blunted by AG490.
Conclusions:
- Arbutin demonstrates a protective role in colitis by inhibiting the JAK2 signaling pathway.
- Arbutin represents a potential alternative therapeutic strategy for colitis treatment.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
9.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.6K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
287
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
287
01:22PI3K/mTOR/AKT Signaling Pathway
4.2K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.2K